Click image to view larger » Potentia Pharmaceuticals is developing a portfolio of drugs that interferes with age-related macular degeneration (AMD) at different stages of its progression. Potentia has licensed its first preclinical compound to launch its pipeline of drugs aimed at AMD: POT-4. Potentia's anti-vascular biotechnology is called Proteus, and as it matures, new compounds will be added to its pipeline and new disease areas will be explored.